Healthcare / BiotechnologyTaiwan
$17.20
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-242.2M · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-4.9%
↓Gross Margin
20.6%
↓Debt/Equity
0.57
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-14.6%
FCF CAGR
—
FCF margin
-17.3%
FCF / Net income
1.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.40B · net income $-239.9M · FCF $-242.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.40B | $1.40B | $1.56B | $1.79B | $2.25B |
| Net Income | $-239.9M | $-239.9M | $-242.8M | $-639.9M | $291.0M |
| EBITDA | $-83.8M | $-83.8M | $-84.3M | $-512.4M | $438.1M |
| EPS | — | — | -0.58 | -1.52 | 0.68 |
| Gross Margin | 20.6% | 20.6% | 28.8% | 23.0% | 39.6% |
| Operating Margin | -22.9% | -22.9% | -19.2% | -18.4% | 4.4% |
| Net Margin | -17.1% | -17.1% | -15.6% | -35.8% | 12.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.57 | 0.57 | 0.50 | 0.57 | 0.37 |
| Current Ratio | 2.12 | 2.12 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-242.2M | $-242.2M | $513.3M | $-1.11B | $-633.2M |
| Returns | |||||
| ROE | -4.9% | -4.9% | -4.6% | -11.7% | 4.8% |
| Valuation | |||||
| P/E | — | — | — | — | 51.54 |
| EV/EBITDA | — | — | — | — | 32.86 |
| P/B | 1.47 | 1.47 | 1.63 | 2.55 | 2.45 |
| Growth & Yield | |||||
| Revenue Growth | -10.0% | -10.0% | -12.8% | -20.7% | — |
| EPS Growth | — | — | 61.8% | -323.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-7.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.58 → n/d
Residual
-7.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.